SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

CCCX is trending as Infleqtion, its quantum technology merger target, garners significant attention for its role in a NASA space mission and a U.S. Department of Energy contract, leading to community discussion around its perceived undervaluation against quantum peers and high expectations for its upcoming merger and NYSE debut as INFQ.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is navigating intense investor speculation ahead of its earnings report, fueling a stark divide between bulls anticipating a significant short squeeze driven by its AI lending model and critics lamenting consistent underperformance and management's perceived lack of communication. The broader fintech sector's volatility and concerns over consumer credit health continue to weigh heavily on community sentiment, making the stock a focal point for both potential rebound and further weakness.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is rallying following its European CE Mark approval for the Eversense 365 CGM and the first commercial integration with the twiist automated insulin delivery system, with the community highly anticipating broader adoption of its superior one-year implantable technology despite historical management concerns and ongoing market volatility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as widespread user frustration mounts over persistent platform outages and trading restrictions, especially with its ThinkorSwim platform. Despite recent positive financial updates and a substantial share buyback program, the community is actively discussing these reliability issues and the possibility of switching to alternative brokers.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a strong Q4 earnings beat and optimistic outlook, with the community highlighting reaccelerated revenue growth and surging RPO driven by both core and AI-native customers. This robust performance is viewed as a significant positive signal for the broader software sector, suggesting a potential end to its recent slowdown.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after bearish 2026 guidance, driven by DefenCath's post-TDAPA reimbursement concerns, caused a significant stock decline. The community is highly critical of management's communication, while simultaneously anticipating updates from an upcoming Analyst Day, a $75 million share repurchase program, and potential legislative support to counter heavy short interest and prove the stock's perceived undervaluation.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending amidst a sharp stock decline following its Q4 earnings report, which revealed strong revenue growth and a substantial reduction in cash burn. This has sparked significant community discussion around whether the market is overlooking the company's fundamental improvements and clearer path to profitability.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending following strong long-term maintenance data for its atopic dermatitis drug, rezpegaldesleukin, which showcased durable efficacy and a favorable safety profile. This has fueled widespread community discussion about the drug's significant market potential and multiple analyst firms revising their outlooks upwards.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following a significant earnings beat and strong outlook, with record user growth, expanding margins, and robust Q1 guidance signaling confidence in its path to sustained profitability. The community is actively debating whether these results, coupled with new AI features and content initiatives, cement its transition from a pure growth story to a high-margin cash generator amidst concerns about valuation and market competition.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is trending sharply higher following positive top-line data from its Phase 2a trial for EVO301, an eczema drug, prompting widespread community discussion around significant upside potential and a short squeeze play, though some traders remain skeptical of its fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 14.9% in January

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 42,044,430 shares, a...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.4% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 7.4% - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell...

<ul class="summary-bullets"><li>The European study is expected to enroll 40 newly diagnosed AML patients.</li><li>Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.</li><li>SLS stock is on track to end in the red in five of the last seven sessions.</li></ul>SELLAS Life Sciences Group Inc (SLS) stock was in the spotlight after it signed an agreement with IMPACT-AML (Acute Myeloid Leukemia) to expand the clinical development of SLS009, a targeted cancer therapy, into Europe.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has been trending down lately and is on track to end in the red in five of the last seven sessions. It was trading 3.2% lower. Last week, investors booked profits amid dilution concerns after Sellas reported $26.5 million in proceeds from the exercise of common stock warrants, in addition to its estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">IMPACT-AML Tie Up</h2>The IMPACT-AML, a pan-European initiative within the EU Mission Cancer program, will conduct a European clinical study evaluating SLS009, providing SELLAS access to multiple clinical sites and a broader patient population. SELLAS aims to leverage the partnership to accelerate enrollment, expand patient access to SLS009, and maintain cost efficiency, it added.The European study is expected to enroll 40 newly diagnosed AML patients with high-risk features to evaluate SLS009 in combination with azacitidine and venetoclax, medications to treat cancer. Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.<h2 class="st-heading-2">Retail Chatter</h2>Despite the intraday decline, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/SLS_jpg_8c87a5394f.webp" alt="SLS.jpg">One user saw the IMPACT-AML development as a positive for the stock and wondered why bears were still selling.<stembedurl>https://stocktwits.com/insidersruleloosersdrool/message/641795770</stembedurl>Another user said validating SLS009 in both the U.S. and the EU simultaneously makes the drug more attractive to a global buyer like Novartis.<stembedurl>https://stocktwits.com/Cresskill198/message/641779078</stembedurl>SLS shares have shot up 345% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA">IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Equity

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3% - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10.3% Higher - Time to Buy...

<ul class="summary-bullets"><li>On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants.</li><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.</li><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) fell for the fourth straight session on Friday as investors resorted to profit taking amid dilution concerns.Shares of the company traded 13% lower at $3.34 at the time of writing, after <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-breaches-5-dollar-level-after-over-3-years/cmxuTsiR4RS">breaching</a> the $5 threshold for the first time in over three years earlier this week.On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants. This is in addition to the company’s estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed disappointment at the company diluting shares of the company by exercising warrants provided it has “sufficient cash” to carry out ongoing trials. However, they expect the price to be back up by February.<stembedurl>https://www.stocktwits.com/jackobull/message/641370638</stembedurl>Another, however, said that there is no “legitimate reason” to sell the stock. “...we longs know this is short lived. &nbsp;VERY short lived. &nbsp;It will explode upward from this oversold action,” they wrote.<stembedurl>https://www.stocktwits.com/Wut_About_Bob/message/641368167</stembedurl><h2 class="st-heading-2"> What Drove The Recent Rally?</h2>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study, and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou said at the time. The announcement kickstarted a rally that mostly sustained through late December and early January.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at significant potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-pharmaceuticals-stock-rallies-after-hours-on-strong-genetic-disorder-drug-sales-kickstart/cmUbnxGR45Z">KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?

Shares of the company traded 13% lower at $3.34 at the time of writing.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.4% - Here's Why...

<ul class="summary-bullets"><li>Headlines from CES reignited enthusiasm around AI hardware and autonomous tech.</li><li>Despite the dip, retail sentiment on Stocktwits toward SPY and QQQ remained bullish.&nbsp;</li></ul>U.S. stock futures were trading in the red early Tuesday as investors balance AI optimism from CES, while awaiting crucial jobs data later this week.As of 3:50 a.m. ET on Tuesday, Nasdaq 100 futures and S&amp;P 500 futures fell 0.1%, and the Dow futures fell 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid normal message volumes.Trending Stocks To Watch Nvidia (NVDA):&nbsp;At CES, Jensen Huang&nbsp;announced Nvidia’s next-generation AI chips, Vera Rubin, a successor to&nbsp;its Blackwell architecture, which would go on sale in the second half of the year. It is also joining the push to develop self-driving cars, reinforcing its position as a full-stack AI platform company, not just a chipmaker.&nbsp; Tesla (TSLA): CEO Elon Musk downplayed concerns around Nvidia’s newly unveiled Alpamayo autonomous driving AI.&nbsp; Advanced Micro Devices, Inc. (AMD)&nbsp;garnered retail attention on Stocktwits after the chipmaker&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-crashes-ces-2026-with-all-out-offensive-against-nvidia/cmxwVexR4Tb">launched</a> a slew of AI chips for computers, data centers, and gaming at the CES trade show in Las Vegas. Intel (INTC)&nbsp;unveiled its latest laptop processors, the Core Ultra Series 3, which are set to roll out in new computers later this month. Also, keep an eye on Chevron (CVX), Exxon Mobil Corp (XOM), amid political developments in Venezuela. OneStream (OS):&nbsp;HG Capital is reportedly nearing a deal to acquire the financial software firm.&nbsp; Sellas Lifesciences (SLS)&nbsp;is the top trending ticker on Stocktwits at the time of writing.&nbsp; Aeva (AEVA)&nbsp;is on the retail radar after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiny-lidar-player-aeva-stock-rockets-over-25-after-hours-on-nvidia-deal/cmxwXUUR4RV">announcing</a> its 4D LiDAR will be integrated into the Nvidia Drive Hyperion platform. PLTR (Palantir) and&nbsp;RCAT (Red Cat Holdings) are trending. Traders are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/red-cat-roars-back-venezuela-speculation-sends-drone-stock-flying/cmxw13MR4Rs">speculating</a> on increased contract awards for surveillance and drone technology.&nbsp; Zeta Global (ZETA)&nbsp;is gaining traction following the collaboration with OpenAI to enhance its marketing platform. And&nbsp;Alumis (ALMS) is scheduled to report topline Phase 3 data for envudeucitinib in plaque psoriasis before the open, with a conference call at 8:00 a.m. ET.&nbsp; Other noteworthy tickers trending on Stocktwits at the time of writing were Amazon (AMZN), Momentus In (MNTS), Bank of America (BAC), Alibaba (BABA), Paramount Skydance (PSKY), and Apteva Therapeutics (APVO) Other Catalysts To Watch With no significant economic releases due Tuesday, traders are expected to continue tracking CES developments and positioning ahead of key jobs data later this week. Siemens is expected to showcase its Industrial Metaverse, while Lenovo CEO is expected to unveil the “AI for All” strategy today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.


SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Show me the results

Stocktwits

Stocktwits Polls

Intense speculation is swirling around an alleged "pfe-integration" subdomain with updated security certificates, interpreted by some as digital breadcrumbs pointing to an imminent Pfizer acquisition.

Traders are eagerly anticipating an Independent Data Monitoring Committee meeting this month, predicting an early halt of the REGAL trial due to overwhelming efficacy of the drug.

Retail investors are uniting to counter perceived market manipulation, highlighting dwindling borrowable shares and increasing fees, attempting to trigger a short squeeze.

Users are questioning why the StockTwits sentiment meter displays "extremely bearish" despite numerous bullish posts, suggesting a data inconsistency or algorithm issue.

Long-term holders emphasize disciplined accumulation and patience, confident that significant price appreciation from upcoming trial results or a buyout will reward their conviction.

Current Price	$3.74
Prev Close	$3.81
Open	$3.81
Dividend Yield	0.00%
50-Day Moving Average	$3.19
Beta	0.92
Avg. Volume	11.53M
PE Ratio	-13.28

52-Week High	$5.18
52-Week Low	$0.9516
Market Capitalization	$542.7M
EPS (Annual)	-$0.5046
Price to Book	10.44
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc